16 / 23
Page 60
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Multiple centers around the world are adopting PSMA based radionuclide therapies for treating advanced stage prostate cancer
patients. Recent anecdotal reports and clinical trial results have been encouraging and have demonstrated personalized approach
and efficacy for PSMA-targeted radionuclide therapies. Both, antibodies and small peptide-based agents as well as beta or alpha
emitters are actively being pursued. Identifying the optimal agent with the highest efficacy and least toxicity for individual
patients, rather than “one size fits all” approach is the need of the hour. Antibody based agents have longer biologic half-lives
and delayed tissue penetration while the peptide-based agents have rapid kinetics that affords only a short time to engage with
the target. Similarly, alpha particles have higher energy to deliver while beta emitters have longer range. Significant experience
has been gained using
177
Lu-PSMA-617 and
177
Lu-J591 while reports/results for
225
Ac-PSMA-617 and
225
Ac-J591 are now getting
published. With multiple options of targeted therapies, comes the need to identify the most suitable one for each patient. The goal
is to personalize the therapies based on the tumor characteristics that suit the need of individual patients.
jbatra1@jhmi.eduUpdates on PSMA targeted radionuclide
therapies for prostate cancer
Jaspreet S. Batra, Russell H Morgan Department of Radiology
and Radiological Sciences
Johns Hopkins Medical Institutions Baltimore, MD
J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-003